Epilepsy Drugs Market is likely to reach nearly USD 5.5 Billion by the year-end of 2021.
Market growth can be attributed to factors such as the rising incidence of neurological disorders, growing disease awareness, an introduction of novel antiepileptic drugs (AEDs), strong government support and initiatives. Moreover, increasing R&D investment and launch of extended-release formulations are further expected to fuel the market growth. However, the high cost of patented drugs, concerns over decreasing healthcare costs as part of government austerity measures, particularly in Europe and low accessibility to antiepileptic drugs in low and middle-income countries, are likely to restrict the market growth.
Vimpat is the undisputed leading drug of Global Epilepsy Drugs Market. It has a market share of nearly 22% in 2016 and is expected that Vimpat will gain its momentum till the forecasting period. Keppra was the second highest market share taker with more than 19% share in 2016 but the prospect of this drug will change due to the patent expiration in 2018 and its share decline to XX% by 2021. It is expected that Lamictal will be second leading drug with nearly XX% share by 2021. Onfi holds the third highest share of the Epilepsy Drugs market, being followed by Depakine by the year-end of 2021.
The research report titled “Epilepsy Drugs Market: Global Demand, Growth Potential & Opportunity Outlook 2021” examines the market, competitive landscape and trends of the Global Epilepsy Drug Market. This report analyzes market data and provides a better understanding of Epilepsy Drugs sales value and demand in the Global Market. Market outlook in value terms for the forecasted period for Epilepsy Drugs Market has been detailed in the report. Key trends in terms of collaborations, partnerships and licensing agreements are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the Global Epilepsy Drugs Market.
The report concludes with the profiles of major players in the Epilepsy Drugs Market such as UCB, EISAI, Pfizer, Sanofi, and Lundbeck. The major market players are evaluated on various parameters such as company overview and latest development and trends in the Epilepsy Drugs Market
Key Topics Covered in the Report
- Worldwide Epilepsy Drugs Market Analysis (2013 – 2021)
- Worldwide Epilepsy Drugs Market Share (2013 – 2021)
- Worldwide Epilepsy Drugs Brand Market Performance (2013 – 2021)
- Epilepsy Drugs Market – Major Deal Types
- Key Companies Analysis
- Key Drivers and Inhibitors of the Epilepsy Drugs Market
Key Epilepsy Drugs Covered in the Report are as follows:
- Vimpat(Lacosamide)
- Keppra(Levetiracetam)
- Briviact(Brivaracetam)
- Lamictal(Lamotrigine)
- Neurontin (Gabapentin)
- Depakine (Sodium Valproate)
- Sabril (Vigabatrin)
- Onfi(Clobazam)
- Fycompa(Perampanel)
- Inovelon/Banzel(Rufinamide)
- Zonegran (Zonisamide)
- Zebinix (Eslicarbazepine Acetate)
Key Companies Covered in the Report are as follows:
- UCB
- EISAI
- Pfizer
- Sanofi
- Lundbeck
Table of Contents
1. Executive Summary
2. Worldwide – Epilepsy Drugs Market Analysis (2013 – 2021)
3. Worldwide – Epilepsy Drugs Market Share (2013 – 2021)
4. Key Drivers and Inhibitors of the Epilepsy Drugs Market
4.1 Market Drivers
4.2 Inhibitors
5. Worldwide – Epilepsy Drugs Brand Market Performance (2013 – 2021)
5.1 Vimpat(Lacosamide) – UCB
5.2 Keppra(Levetiracetam) – UCB
5.3 Briviact(Brivaracetam) – UCB
5.4 Lamictal(Lamotrigine) – GlaxoSmithKline
5.5 Neurontin (Gabapentin) – Pfizer
5.6 Depakine (Sodium Valproate) – Sanofi
5.7 Sabril (Vigabatrin) – Lundbeck
5.8 Onfi(Clobazam) – Lundbeck
5.9 Fycompa(Perampanel) – EISAI
5.10 Inovelon/Banzel(Rufinamide) – EISAI
5.11 Zonegran (Zonisamide) – EISAI
5.12 Zebinix (Eslicarbazepine Acetate) – EISAI
6. Epilepsy Drugs Market – Major Deal Types
6.1 Epilepsy Drugs Market – Collaboration Deals
6.2 Epilepsy Drugs Market – Licensing Agreement
6.3 Epilepsy Drugs Market – Partnerships Deals
7. Key Companies Analysis
7.1 UCB
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.1 EISAI
7.1.1 Business Overview
7.1.2 Epilepsy Drugs – Latest Development & Trends
7.2 Pfizer
7.2.1 Business Overview
7.2.2 Epilepsy Drugs – Latest Development & Trends
7.3 Sanofi
7.3.1 Business Overview
7.3.2 Epilepsy Drugs – Latest Development & Trends
7.4 Lundbeck
7.4.1 Business Overview
7.4.2 Epilepsy Drugs – Latest Development & Trends
The report is readily available and can be dispatched immediately after payment confirmation.
More Information @ https://dpiresearch.com/reports/epilepsy-drugs-market-global-demand-growth-potential-opportunity-outlook-2021/
Customization of the Report:
DPI Research provides customization of the report as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.
DPI Research is a leading market research publisher which offer bespoke market research reports, custom research and consulting services across multi geographies and industry verticals. We deliver a wide range of cutting-edge research solutions that help organizations in making better decisions of the business to business needs.
DPI Research provides a high standard of business research reports to the clients across industry verticals comprising Life Sciences, Information Technology, Telecom & Internet, Food Beverages & Agriculture, Travel & Tourism, Consumer Goods & Retail, Education and Social Sciences. We are committed to using advanced analytical tools and methodologies to help clients with crucial industry information for decision making.
DPI Research approaches for business research led by a team of dynamic industry experts. DPI Research provides real insight for effective decisions to help business with the help of current source and accurate data available in the market. DPI Research reaches across the globe with global standards from established markets in North America and Europe to emerging markets in South America, Asia-Pacific, Middle East, and Africa to provide the best business solutions.
Contact Us:
Maria Rai
Head of Business Development
DPI Research | Web: https://dpiresearch.com
Direct Line: +91-766-764-8693
E-mail: sales@dpiresearch.com